Attovia Therapeutics recently went public with a market cap of about $288 million, focusing on its Attobody platform that creates biparatopic antibodies. Its lead drug, ATTO-1310, targets IL-31, a cytokine linked to chronic itch and atopic dermatitis, currently in Phase 1 trials. The company also has two other candidates in development for inflammatory and pruritic diseases, backed by $255.8 million in funding. Upcoming milestones include Phase 1 results for ATTO-1310 and IND clearance for ATTO-2306 in early 2027, which will be critical for validating its platform and commercial prospects.
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Apple Inc., valued at $4.49 trillion, is seeing growing investor confidence with a new analyst price target of $400, suggesting a 30.75% upside from its current price of $305.93. Institutional investors like First Nebraska Trust Co. and others are in...
Apple's stock, currently priced at $305.93, appears overvalued despite strong recent earnings driven partly by temporary factors like tariff refunds. The company reported its ninth consecutive earnings beat with significant growth in iPhone, Mac, and...
VivoPower PLC announced plans to spin off its non-Nordic AI data center assets into a new independently capitalized company headquartered in Singapore. This new entity will focus on data center assets in the UAE, Oman, Saudi Arabia, Malaysia, and the...
Strategy raised $333.7 million by selling shares last week but did not buy or sell any bitcoin, marking the eighth consecutive week without bitcoin transactions. The funds raised were used entirely for preferred dividends, preferred stock buybacks, a...
